Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge

The chronic myeloid leukemia (CML) therapeutic landscape has dramatically changed with tyrosine kinase inhibitor (TKI) development, which allows a near-normal life expectancy. However, long-term TKI exposure has been associated with persistent adverse events (AEs) which negatively impact on quality...

Descripción completa

Detalles Bibliográficos
Autores principales: Iurlo, Alessandra, Cattaneo, Daniele, Bucelli, Cristina, Breccia, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867069/
https://www.ncbi.nlm.nih.gov/pubmed/33535564
http://dx.doi.org/10.3390/jcm10030515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867069/
https://www.ncbi.nlm.nih.gov/pubmed/33535564
http://dx.doi.org/10.3390/jcm10030515

Ejemplares similares